Puma Biotechnology
Takeda farms out cancer drug alisertib to Puma Biotech -
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology Inc
Puma Biotechnology
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Jobs with Puma Biotechnology
Puma Biotechnology
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
